The Archive · 4 posts
High-quality healthcare solutions! 💊 Hikma Pharmaceuticals (HIK) delivers essential medicines worldwide, redefining excellence on the LSE. 🌟
Hikma delivered stronger margins and cash flow in H1 2026, although Injectables remained under pressure and net debt increased.
Showing 3 of 4 posts
Hikma reaffirms 2026 guidance after strong Q1, announces inhalation partnership to accelerate generic Ellipta® programme.
JoshuaApril 23, 2026
Hikma delivers solid growth, a chunky $250m buyback, and a leadership shake-up. Dividend lifted 5% to reward shareholders.
JoshuaFebruary 26, 2026
Hikma H1 revenue up 6%, profit dips 7%. Confirms 2025 guidance & hikes dividend 12%. Strategic progress on track.
JoshuaAugust 7, 2025
August 6, 2026